The FDA is warning patients who have had their gallbladder removed to avoid using eluxadoline for irritable bowel syndrome, citing two deaths among such patients.
The FDA reported that eluxadoline (Viberzi, Allergan) has been linked to severe pancreatitis and death in patients without a gallbladder.
“Symptoms of pancreatitis have occurred with just one or two doses of Viberzi at the recommended dosage for patients who do not have a gallbladder (75 mg) and who do not consume alcohol,”